Dynamic Biomarkers for Deep Immune Phenotyping in Autoimmune Disease
Autoimmune diseases present with a wide range of clinical symptoms, severity, and therapeutic response, complicating the diagnosis and treatment of patients. Small molecule biomarkers read out dynamic changes that occur with immune system activation, dysregulation, and response to drug exposure. These biomarkers may be leveraged to deeply phenotype the immune system and even classify autoimmune disease subtypes, monitor for therapy-related immune adverse events, and predict response to targeted therapies.
In this webinar, we will discuss how high throughput mass spectrometry-based methods can be applied to broadly assay thousands of metabolites and lipids per sample at a time, to read out early and subtle changes in immune cell populations, their activation and function, and dynamic response in the setting of autoimmune disease and treatment. When integrated with other multi-dimensional omics data, this information can drive improved understanding of the mechanisms underlying autoimmune disease variability and facilitate timely intervention with precision therapies.
You will learn:
- Why discovery of dynamic small molecule biomarkers in the setting of autoimmunity can drive greater understanding of disease mechanisms and subtypes, patient response, and drug safety
- How emerging technologies are now enabling rapid measure of dynamic small molecule biomarkers at population level scale
- How integration of small molecule biomarkers with other dynamic readouts, including cytokine measures, can inform development of safer, more efficacious treatments that target the underlying pathways of autoimmune diseases
Speaker Biographies
Mo Jain MD, PHD, Founder & CEO at Sapient
Dr. Jain is a physician-scientist with more than 20 years of expertise in physiology, biomedicine, engineering, computational biology, and mass spectrometry-based metabolomics. Prior to founding Sapient, he formed and was director of Jain Laboratory at the University of California San Diego (UCSD). There he led a multi-disciplinary research team of chemists, engineers, mathematicians, epidemiologists, and physicians to develop next-generation rapid liquid chromatography-mass spectrometry (rLC-MS) systems to probe the non-genetic landscape of disease across population-scale human studies. Dr. Jain founded Sapient in 2021 as a spinout of Jain Laboratory to expand upon the mission of accelerating human discovery and drug development with large-scale discovery metabolomics.
Tanya Nguyen, PHD, Head of Scientific Operations, Sapient
Dr. Nguyen is a clinician-scientist with over 13 years of research experience, having been principal investigator on a number of National Institutes of Health- and Foundation-supported multi-site clinical trials. Dr. Nguyen’s work has leveraged multi-omics discovery within the context of human biosampling to uncover new biomarkers for disease diagnosis and treatment. At Sapient, Dr. Nguyen acts as a liaison between scientific, business, and operational teams overseeing key customer relationships and partnerships.